Healthcare, Pharma & Life Sciences

East Lansing – October 29, 2026 -- The Inner Circle has named David R. Neff, DO, a Pinnacle Lifetime Member for contributions in medicine, education and research, citing a career of more than 45 years that spans clinical practice, pharmaceutical leadership and academia.

Neff spent 15 years in pharmaceutical leadership after 20 years in clinical practice

Neff worked in direct clinical practice for about 20 years before moving into the pharmaceutical industry. There he held leadership roles for 15 years, including Medical Science Liaison at Merck and Senior Chief Medical Director for Medicaid Medical Affairs.

When the COVID-19 pandemic emerged, he returned to patient care in urgent care and family medicine settings.

Prairieville, Louisiana – October 29, 2026 -- Hope Charities is backing H.R. 10549, a House bill that would bar commercial health plans from steering patients toward insurer- or PBM-owned specialty pharmacies, with the rules taking effect for plan years beginning on or after January 1, 2029.

Rep. Neal Dunn (R-FL) introduced the Patients Choice in Specialty Pharmacy Act on September 24, 2026, with Rep. Joe Wilson (R-SC) as an original cosponsor. The bill is with the House Committee on Energy and Commerce. Hope Charities is urging Congress to act and is asking members to cosponsor.

Basel – October 29, 2026 -- Genedata, a Danaher company, launched an electronic lab notebook (ELN) built natively into its biopharma R&D software platform, replacing standalone notebook tools with a single scientific record spanning discovery and development.

Genedata embeds the ELN in its existing platform data model

The ELN links directly to molecules, samples, process parameters, and assay and analytics results already managed in the platform. This cuts manual data transfers and inconsistencies between applications. It supports workflows for biologics and complex modalities including ADCs, bispecifics, cell and gene therapies, and peptides.

Experiment documentation stays tied to a candidate's full development history. That history runs from design and molecular biology through screening, engineering, expression, purification, and analytics to upstream and downstream process development, formulation, and analytical development.

Oakland – October 29, 2026 -- Kaiser Permanente has awarded a $15 million charitable grant to UCSF Benioff Children's Hospital Oakland to build 20 private inpatient behavioral health rooms, adding capacity to treat approximately 700 children and adolescents a year.

Grant funds a 21,300-square-foot behavioral health wing

The money will pay for construction of the wing as part of the hospital's modernization project. The plan includes an outdoor therapy space and a therapeutic roof garden. The wing is expected to open in 2031.

Oakland hospital gains its first dedicated acute psychiatric beds

The project creates inpatient behavioral health treatment capacity at the facility for the first time. The hospital serves children and families from across Northern California regardless of ability to pay, and it provides specialized pediatric services that many community hospitals cannot offer.

NEW YORK – October 29, 2026 -- The Huntington's Disease Foundation (HDF) has awarded $2 million across two 2026 Transformative Research Awards (TRAs), giving $1 million each to teams targeting the toxic huntingtin protein behind Huntington's disease (HD).

HDF typically funds one TRA a year. CEO Meghan Donaldson said the "extraordinary potential" of both proposals warranted funding each. The foundation attributes the expanded round to new major donors.

Harding team pursues small molecules to clear huntingtin

Dr. Rachel Harding of the Structural Genomics Consortium and the University of Toronto leads one funded collaboration. Her project, "Structure-Guided Development of Small Molecule Therapeutics Targeting the Huntingtin Protein," builds on a small molecule that binds directly and selectively to huntingtin.

Toronto – October 29, 2026 -- Deloitte Consulting LLP will demonstrate live how AI-enabled case intake can handle incoming adverse event data in pharmacovigilance during an Xtalks webinar on Wednesday, October 29, 2026, at 1pm EDT (10am PDT).

Deloitte executives to demo ElevateSafety and Detective on Converge

Cyle Connell, Associate Vice President of Product Management for ElevateSafetyTM, and Ellen O'Dea, Senior Manager, both of Deloitte Consulting LLP, will lead the session. The demonstration covers ElevateSafetyTM and Detective, powered by ConvergeTM by Deloitte. It will show AI-enabled detection, data structuring, quality checks and routing across diverse data sources.

PONTE VEDRA, Fla. – October 29, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) is seeking out-licensing or co-development partners for CAD-1005, a 12-LOX inhibitor it describes as Phase 3-ready, after a competitor's late-stage trial in cardiac surgery-associated acute kidney injury (CSA-AKI) was discontinued for lack of efficacy.

Cadrenal extends CAD-1005 from HIT to a $1 billion-plus U.S. CSA-AKI market

The company is consolidating its Cardiac Acute Critical Care franchise around a dual-indication plan. CAD-1005 will be developed for heparin-induced thrombocytopenia (HIT) and for CSA-AKI, which Cadrenal sizes at more than $1 billion in the U.S. It claims first-in-class positioning in CSA-AKI following the competitor's Phase 3 discontinuation. The source does not name the competitor or the failed mechanism.

PONTE VEDRA – October 29, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has launched a structured partnering process for three cardiovascular assets while holding about $4.2 million in cash, enough to fund operations only through the first quarter of 2027.

The company is exploring development, licensing and commercialization deals for CAD-1005, frunexian and tecarfarin. It is pursuing out-licensing, portfolio monetization and commercial co-development rather than funding large late-stage trials on its own. Cadrenal said it will not start a clinical trial unless funding to complete that trial is in place.

Second-quarter net loss narrows to $3.3 million on lower R&D spending

Research and development expenses fell to $0.7 million in the quarter ended June 30, 2026, from $1.1 million a year earlier. General and administrative expenses were $2.6 million, against $2.7 million in the prior-year period.

IRVINE – October 29, 2026 -- SBC Medical Group Holdings (Nasdaq: SBC) will put its AI-driven longevity strategy in front of Asian investors this month, with CFO and COO Yuya Yoshida presenting at Cantor Fitzgerald Hong Kong's inaugural Asia Longevity Forum on October 26, followed by investor meetings on October 27 and a non-deal roadshow on October 28.

Yoshida takes keynote and panel slots at a forum with more than 40 companies

The two-day Cantor HK Asia Longevity Forum 2026 runs October 26-27 at The Murray Hotel in Central, Hong Kong. More than 40 public and private companies are expected to attend. Yoshida will speak in the keynote and panel sessions on day one. Forum themes include the longevity economy, AI and digital health adoption, and building Asia's next-generation healthcare system.

SAN FRANCISCO – October 29, 2026 -- Nektar Therapeutics (Nasdaq: NKTR) will report third-quarter 2026 financial results for the period ended September 30 on Thursday, November 12, 2026, after U.S. markets close.

CEO Howard Robin to host 5:00 p.m. ET results call

President and Chief Executive Officer Howard Robin will lead a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the quarter.

Lead candidate REZPEG is being evaluated in three indications

Nektar describes itself as a clinical-stage biotechnology company focused on the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Its lead candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata and Type 1 diabetes mellitus.